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Abstract
Purpose The study objectives are to translate the 21-item
Cognitive Symptom Checklist-Work (CSC-W21) to Dutch
(CSC-W DV) and to validate the CSC-W DV in working
cancer patients.
Methods The CSC-W21 was cross-culturally translated and
adapted to a Dutch version. In this 19-item version, the dichot-
omous response option was changed to an ordinal five-point
scale. A validation study of the CSC-W DV was conducted
among cancer patients who had returned to work during or
following cancer treatment. Internal consistency (Cronbach’s
α), structural validity (exploratory factor analysis) and con-
struct validity (hypothesis testing) were evaluated.
Results In a cohort of 364 cancer patients, 341 (94 %) com-
pleted the CSC-W DV (aged 50.6±8.6 years, 60 % women).
Exploratory factor analysis revealed two subscales ‘working
memory’ and ‘executive function’. The internal consistency of
the total scale and subscales was high (Cronbach’s α=0.93–
0.95). Hypothesis testing showed that self-reported cognitive
limitations at work were related to work functioning
(P<0.001), fatigue (P=0.001) and depressive symptoms
(P<0.001), but not to self-rated health (P=0.14).
Conclusions The CSC-W DV showed high internal consis-
tency and reasonable construct validity for measuring work-
specific cognitive symptoms in cancer patients. The CSC-W
DV was associated in expected ways with work functioning,
fatigue and depressive symptoms.
Implications for Cancer Survivors It is important to enhance
knowledge about cognitive symptoms at work in cancer pa-
tients, to guide and support cancer patients as good as possible
when they are back at work and to improve their work func-
tioning over time.
Keywords Cancer . Oncology . Cognitive symptom
checklist . Work functioning . Internal consistency . Validity
Background
Cognitive symptoms are common among cancer patients and
persist over time [1]. Cognitive symptoms can be attendant to
the tumour or a result of treatment [1]. While 64 % return to
work within 6 months after diagnosis [2], cancer patients can
experience a reduced quality of life and function due to cog-
nitive symptoms [1, 3]. Cognitive symptoms are associated
with fatigue, depression and perceived health status [4–6].
Additionally, cognitive symptoms or function are negatively
related to job performance, work ability, productivity and sus-
tainable work [3, 7–12]. In the Netherlands, there is no native
or cross-culturally adapted and validated self-report measure
of cognitive functioning in the context of work for cancer
patients available.
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Cognitive deficits are usually identified by neuro-
psychological assessment [13]. To assess the role of cognitive
limitations in the context of work, a valid and easy-to-use self-
report measure offers a practical advantage over timely and
detailed neuro-psychological assessment. Self-report mea-
sures of cognitive function have been related to work output
in cancer patients [10].
Several self-report instruments have been developed to
measure cognitive symptoms in cancer patients [14, 15], in-
cluding the Cognitive Symptom Checklist-100 (CSC-100).
Based on the CSC-100, a 59-item work-specific cognitive
symptoms questionnaire (CSC-W59) was developed [16].
To reduce the measurement burden, a 21-item version (CSC-
W21) was developed and validated in working breast cancer
survivors [17].
When using an established questionnaire in a different cul-
tural context, it has to be translated, adapted and validated [18,
19]. Recently, the CSC-W21 has been translated and adapted
for use in China [20]. The objective of this study is to cross-
culturally translate and adapt the CSC-W21 into Dutch and to
assess the reliability (i.e. internal consistency) and validity (i.e.
structural and construct) of the CSC-W Dutch version (CSC-
W DV). The COnsensus-based Standards for the selection of
health status Measurement INstruments (COSMIN) taxono-
my was used for the study design [21–23].
Methods
Cross-cultural translation and adaptation
A cross-cultural translation and adaptation of the CSC-W21
[18] was performed according to a standard systematic proce-
dure, including forward translation, synthesis, back-transla-
tion, consolidation by an expert committee and pre-test [18,
19], ultimately leading to the CSC-W DV. During the transla-
tion and adaptation process, three original items (2 ‘difficulty
remembering my train of thoughts as I am speaking’, 5 ‘diffi-
culty remembering a word I wish to say’ and 6 ‘difficulty
remembering the name of a familiar object or person’,
Table 2) were discussed with the professional translator and
the original author (MF) regarding the meaning of ‘remem-
bering’. Two original items (9 ‘difficulty understanding a sys-
tem’ and 12 ‘difficulty understanding systems and models’,
Table 2) were difficult to distinguish due to conceptual over-
lap, and after consultation with MF, these items were
combined.
A pre-test was performed with 13 cancer patients (ageM=
51.2 years, SD=6.0; 9 women) who had returned to work for
at least 12 h a week after sickness absence. The CSC-W21
was developed to measure work-specific cognitive symptoms
in cancer patients [18]. Working cancer patients were selected
to explore the understandability, applicability and
completeness of the items in working cancer patients. Partic-
ipants had no difficulties in understanding the items and no
concerns regarding applicability and completeness.
Final questionnaire
The final CSC-W DV contained a set of 20 questions specific
to a person’s work tasks and measured work-specific cogni-
tive symptoms. To obtain a wider distribution in scores and to
have a more responsive measure [24], the response options
were changed from a dichotomous scale (i.e. yes or no) to
an ordinal five-point scale, ranging from 0=never to 4=al-
ways. The response option ‘Does not apply to my job’ was
added to enable cancer patients to answer, even though a par-
ticular symptom was not relevant to their job. Total scores
were obtained by summing the scores on each item, divided
by the number of items and then multiplied by 25 to obtain
scores between 0 and 100, with higher scores indicating more
cognitive symptoms (i.e. more limitations). The scores on
‘Does not apply to my job’ were transformed to missing
values. If answers on 20 % or more of the items were missing,
the total score was set to missing.
Measurement properties of the CSC-W DV
Subjects and setting
The final version of the CSC-W DV was administered at
baseline in the Work Life after Cancer (WOLICA) study.
WOLICA is an ongoing longitudinal cohort study in the Neth-
erlands, investigating cancer patients’ work functioning. Can-
cer patients aged 18–65 years, who had returned to paid work
(during or following treatment for cancer) in the past 3 months
for at least 12 h per week, and who had a history of paid work
for at least 1 year prior to diagnosis, were eligible for
WOLICA if able to complete a questionnaire in Dutch. Pa-
tients with recurrent cancer and patients treated with hospice
care were excluded, because the study might be too burden-
some for these cancer patients given the prognosis and the
timeline of the study. Moreover, cancer patients in hospice
care are not likely to be actively employed.
Occupational physicians (OPs; working at occupational
health services) informed eligible cancer patients about
WOLICA and forwarded the name and address of interested
patients to the research team. The research team decided about
the in- or exclusion of the participant. The cancer patients
received an information letter, an informed consent form and
the baseline questionnaire. Patients received no incentive for
participation. All procedures were reviewed and approved by
the Medical Ethical Committee of the University Medical
Center Groningen (M12.125242).
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Data collection
Participants provided information on age, gender, education
(low=primary, junior secondary vocational and junior general
secondary education; medium=senior secondary vocational
education and senior general secondary education; high=
higher professional education, college and university), cancer
diagnosis and cancer treatment.
Work functioning was measured with the 27-item Work
Role Functioning Questionnaire (WRFQ 2.0, α=0.96) [25],
designed to measure perceived difficulties in meeting work
demands among workers given their physical health or emo-
tional problems [25, 26]. The recall period is 4 weeks, and the
response options range on a five-point scale from 0=difficult
all the time to 4=difficult none of the time, with an additional
response option ‘Does not apply to my job’. A total score was
calculated by summing the scores on each item, divided by the
number of items and then multiplied by 25 to obtain scores
between 0 and 100, with higher scores indicating better work
functioning. The scores on ‘Does not apply to my job’ were
transformed to missing values. If more than 20 % of the items
were left unanswered, scores were set as missing. Work func-
tioning was classified as ‘high’ (>90), ‘medium’ (75–89) and
‘low’ (<75) [27].
Fatigue was measured with the 8-item subscale of the
Checklist Individual Strength (CIS-8) [28, 29] designed to
measure general severity of fatigue (α=0.88). The recall peri-
od was 2 weeks with a seven-point response option scale from
1=yes that is true to 7=no that is not true. A total score was
calculated by summing the items, with higher scores indicat-
ing more severe fatigue [28]. The total score was divided in
tertiles.
Depression was measured with the 9-item Patient Health
Questionnaire-9 (PHQ-9) [30, 31], designed to measure de-
pression for non-psychiatric settings, matching the Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV) criteria
of major depression. The recall period was 2 weeks, and the
response options ranged from 0=not at all to 3=nearly every
day. A total score was calculated by summing the items, and
scores were dichotomized (1/0) as ‘low’ (<10) versus ‘high’
(10 or above, indicative of clinical depression) [30, 31].
General health was measured with the single SF-36 item
‘In general, how would you rate your health?’ [32]. The re-
sponse options range on a five-point scale from 0=excellent to
4=poor. Scores were dichotomized (1/0) as ‘high’ (excellent/
very good/good) versus ‘low’ (fair/poor).
Statistical analysis
Structural validity Exploratory factor analyses (EFA) were
performed to examine the CSC-W DV subscale structure
using principal component analysis (PCA) with oblique rota-
tion (direct oblimin). A combination of the scree plot,
eigenvalues, factor loadings and interpretation of the factors
was used to decide on the number of factors. Items were ex-
plored for factor loading on its own factor (good if >0.5) and
other factors (good if <0.3). Also, item inter-correlations were
explored (ideal between >0.2 and <0.8) [24]. An item was
excluded if it did not meet at least two of the above criteria
and was not considered conceptually important.
Measurement characteristics CSC-W DV mean scores,
standard deviations (SD), range and percent at floor/ceiling
were presented for the total score and subscales. If more than
15 % of the participants reported the lowest or highest scores,
floor and ceiling effects were considered [33].
Reliability CSC-W DV internal consistency was measured
with Cronbach’s alpha, calculated for the total score and for
each subscale (ideal >0.70) [24].
Construct validity To determine the expected associations
with related constructs, four hypotheses were assessed as
follows:
1. Cancer patients with low work functioning report higher
levels of cognitive symptoms than cancer patients with
high work functioning.
2. Cancer patients with a high fatigue level report higher
levels of cognitive symptoms than cancer patients with a
low fatigue level.
3. Cancer patients with a high level of depressive symptoms
report higher levels of cognitive symptoms than cancer
patients with a low level of depressive symptoms.
4. Cancer patients with low self-rated health report higher
levels of cognitive symptoms than cancer patients with
high self-rated health.
Between-group differences were tested with t tests (two
groups) or ANOVA (multiple groups). All analyses were per-
formed with SPSS software (version 22).
Results
Sample characteristics
A total of 364 cancer patients participated in WOLICA; data
of 341 (94 %) patients (61 % women) with a mean age of 50.6
(SD=8.6) years who completed the CSC-W DV were includ-
ed in the analyses. Most patients were diagnosed with breast
cancer (45 %) or colorectal cancer (12 %). At inclusion, pa-
tients were diagnosed with cancer for 10.7 (SD=6.3) months
and almost 70 % (n=234) had completed treatment (Table 1).
The median time back at work was 2 months. Patients were
working on average 17.1 h (SD=14.3) per week. Cancer
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patients reported that it was difficult to meet the demands of
the job due to health problems 22 % of the time (WRFQ M=
77.7, SD=17.4). Twenty-nine percent reported aWRFQ score
of above 90, indicating little difficulty meeting work demands.
The majority (76 %) reported good to excellent health. Cancer
patients reported a mean fatigue score of 30.3 (SD=11.4).
Patients had a mean depression score of 4.7 (SD=3.8), and
12 % (n=40) reported relatively high depressive symptoms,
indicative of clinical depression (Table 1).
Structural validity
All 20 CSC-W DV items were included in an exploratory
factor analysis (EFA) with 1 fixed factor. Reasonable total
scale fit (factor loadings between 0.684 and 0.790) was ob-
served. A three-factor solution did not replicate the original
CSC-W21 three-factor structure [17]. A two-factor solution
worked best (Table 2), with a ‘working memory’ subscale
containing items from the original CSC-W21 ‘working mem-
ory’ subscale and an ‘executive function’ subscale containing
items from the CSC-W21 ‘executive function’ and ‘task com-
pletion’ subscales. Because the item, ‘difficulty staying with a
task until completion’, did not meet the inclusion criteria, it
was removed. Consequently, the final CSC-WDV version has
19 items, with the subscales working memory (8 items) and
executive function (11 items).
Measurement characteristics
The mean total scale score was 25.1 (SD=15.8). Working
memory had the highest scale score (M=32.2, SD=19.0).
Floor and ceiling effects were not observed. Inter-item corre-
lations were between 0.3 and 0.8. Executive function had the
highest number of missing or ‘not applicable’ scores (Table 3).
Reliability
The Cronbach’s alpha for the total scale was 0.95 (Table 3).
Construct validity
Cancer patients with low work functioning had higher CSC-
W DV scores (indicating a greater number of cognitive prob-
lems at work) than those with high work functioning
(Table 4). Cancer patients who reported a high fatigue level
and/or depressive symptoms had higher CSC-W DV scores
than those with a low level of fatigue and/or depressive symp-
toms. The CSC-W DV scores did not differ between cancer
patients reporting low and high self-rated health.
Discussion
The original 21-item CSC-W21 was translated and adapted to
the Dutch context by using a standardized systematic
Table 1 Sample characteristics (n=341)
Socio-demographics
Gender, n (%)
Male 132 (39)
Female 205 (61)
Age in years, M (SD) 50.6 (8.6)
Education, n (%)
Low 80 (24)
Medium 120 (36)
High 134 (40)
Health characteristics
Cancer type, n (%)
Breast cancer 153 (45)
Colon cancer 40 (12)
Lymph node cancer 31 (9)
Prostate and testicular cancer 29 (9)
Other types of cancer 87 (25)
Months since diagnosis, M (SD) 10.7 (6.3)
Treatment completed, n (%)
Yes 234 (69)
No 107 (31)
Type of treatment, n (%)
Surgery 54 (17)
Chemotherapy 20 (6)
Surgery and chemotherapy 50 (15)
Surgery and radiation 41 (12)
Surgery, chemotherapy and radiation 66 (20)
Surgery, chemotherapy, radiation and hormonal therapy 47 (14)
Other combinations of treatment 53 (16)
WRFQ (range 0–100)
M (SD) 77.7 (17.4)
High, n (%) 93 (29)
Medium, n (%) 111 (35)
Low, n (%) 114 (36)
Fatigue, M (SD) (range 8–56)
Total (n=290) 30.3 (11.4)
Low (n=114) 17.6 (5.3)
Medium (n=113) 30.6 (2.9)
High (n=113) 43.0 (5.3)
Depressive symptoms (range 0–27)
M (SD) 4.7 (3.8)
Low, n (%) 301 (88)
High, n (%) 40 (12)
Self-rated health, n (%)
High 256 (76)
Low 79 (24)
Mmean, SD standard deviation; WRFQ Work Role Functioning Ques-
tionnaire, RTW return to work
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procedure for the translation and cross-cultural adaptation.
This resulted in a final 19-item CSC-W Dutch version
(CSC-WDV) with questions specific to a person’s work tasks,
for measuring work-specific cognitive symptoms. The CSC-
W DV contained two subscales (i.e. working memory and
executive function) and showed good reliability without floor
or ceiling effects. Three of four hypotheses to test the construct
validity were confirmed, showing that the CSC-W DV was
able to distinguish between groups with different levels of
work functioning, fatigue and depression. No significant dif-
ference was found for self-rated health. The observation that
almost all participants (94 %) completed the questionnaire
suggests that the measure may have been seen as relevant
and/or that the items were unambiguously formulated [22].
The main differences between the CSC-W DV and the
existing CSC-W versions [17, 20] are the response options
and the validation populations. The dichotomous response
option was changed to an ordinal five-point scale. It was as-
sumed that more response options would lead to a more
refined self-evaluation of cognitive function at work [24]. De-
spite the differences in response set in the original and the
cross-culturally adapted instrument, similar measurement
properties (e.g. internal consistency and factor structure) were
found. Although it is necessary to take this change in response
set into account, the use of an expanded response set did not
change the main measurement properties of the questionnaire
and thereby, comparison of the data across languages is pos-
sible. In addition, it might be possible to dichotomize the
answer categories for the comparison of data across lan-
guages. The three CSC-W versions were validated in popula-
tions with different types of cancer diagnosis, different case
definitions and differences in cultures and languages. In the
current study, cancer patients with all types of cancer were
included during or following treatment, while the other ver-
sions were validated only in breast cancer patients following
primary treatment [17, 20]. The CSC-W DV showed cogni-
tive problems at work in a heterogeneous group of cancer
patients at work, not only in breast cancer patients.
Table 2 Factor loadings Cognitive Symptom Checklist-Work Dutch version (n=341)
CSC-W DV CSC-
W21
Items Factor 1 working
memory
Factor 2 executive
function
1 1 I have difficulty remembering what I intended to write 0.802 0.052
2 2 I have difficulty remembering my train of thought as I am speaking 0.841 −0.045
3 3 I have difficulty remembering the content of telephone conversations 0.841 −0.001
4 4 I have difficulty remembering the content of conversations and/or meetings 0.775 0.102
5 5 I have difficulty remembering a word I wish to say 0.816 −0.037
6 6 I have difficulty remembering the name of a familiar object or person 0.851 −0.068
7 7 I have difficulty remembering information that is ‘on the tip of my tongue’ 0.796 0.011
8 8 I have difficulty remembering things someone has asked me to do 0.598 0.256
9 9/12a I have difficulty to understand that specific tasks along to a larger whole −0.001 0.774
10 10 I have difficulty understanding how a task fits into a plan or system −0.110 0.890
11 11 I have difficulty knowing where to look for information to solve a problem −0.112 0.917
12 13 I have difficulty figuring out how a decision was reached −0.198 0.955
13 14 I have difficulty using new information to re-evaluate what I know 0.095 0.777
14 15 I have difficulty considering all aspects of what I hear or see instead of
focusing on only one part
0.195 0.688
15 16 I have difficulty understanding what a problem is when it occurs and
clearly stating what the problem is
0.144 0.651
16 17 I have difficulty following the flow of events 0.356 0.514
17 18 I have difficulty understanding graphs or flowcharts 0.233 0.587
18 19 I have difficulty completing all steps of a task or activity 0.326 0.543
20b I have difficulty staying with a task until completion 0.458 0.350
19 21 I have difficulty putting steps in order such that the most important steps are done first 0.165 0.637
The italic numbers indicate items that grouped together in the final CSC-W DV. Extraction method: principal component analysis. Rotation method:
Oblimin with Kaiser normalization
a Due to conceptual overlap, items 9 and 12 (original Cognitive Symptom Checklist–Work 21) were combined into item 9 (Cognitive Symptom
Checklist-Work Dutch version, i.e. CSC-W DV)
bNot included in the CSC-W DV
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Despite the differences in versions and populations, similar
measurement properties were found. The internal consistency
and factor structure of the CSC-W DV were comparable de-
spite different cultures and the fact that the items in the orig-
inal subscales ‘executive function’ and ‘task completion’ in
the CSC-W DV both loaded on ‘executive function’. Follow-
up research could develop a shorter list, given the high
Cronbach’s alpha’s and the fact that two items (i.e. original
items 17 ‘difficulty following the flow of events’ and 19 ‘dif-
ficulty completing all steps of a task or activity’, Table 2)
loaded high on both factors.
Patients with low work functioning reported higher
CSC-W DV scores than cancer patients with high work
functioning. This is in line with previous findings that
higher scores on the CSC-W59 were correlated with
higher scores on work output scales of the WLQ, indi-
cating worse work outcomes in working breast cancer
survivors [10]. We found that CSC-W DV scores were
also related to fatigue and depression. According to
Valentine et al., problems with cognitive functioning, fa-
tigue and depression are very common in cancer patients
[5]. Previous research in colorectal cancer patients also
showed associations between self-reported cognitive
function and fatigue, anxiety and depression [4]. Li
et al., [6] reported fatigue in breast cancer patients as
an important risk factor for perceived cognitive
impairment.
Although cancer patients who reported low self-rated
health reported more cognitive symptoms, the difference
was not statistically significant when compared to patients
with high self-rated health. This may indicate that cognitive
functioning at work is not represented in self-rated health. An
alternative explanation is that cancer patients with poorer
health were excluded, because the inclusion criteria of the
present study required that cancer patients had to work for
>12 h a week. It is also possible that while a relationship exists
among symptom burden measures of depression and anxiety
and cognitive function, overall or general health is not neces-
sary and sufficient for cognitive function at work. This needs
to be further explored.
In this study, cancer patients were only included when
they had returned to work. This means that the results of
the current study are only generalizable to cancer pa-
tients at work and not to the true incidence of cognitive
symptoms among cancer patients in general; this may be
underestimated. Patients were diagnosed with various
types of cancer and some cancer patients were on treat-
ment, while others had completed treatment or received
adjuvant therapy. The variation in treatment can be a
study limitation because some adjuvant therapies can im-
pact cognitive functioning [34]. However, this study was
not designed to determine whether scores were related to
type of treatment or a specific cancer. Future research is
needed to examine the consistency of measurement prop-
erties of the CSC-W DV across cancer type and treat-
ments. Another limitation is that we did not conduct
concurrent neuro-psychological assessments, which may
be a more objective standard to validate the CSC-W DV.
Interestingly, Calvio et al. [10] observed that work-
specific CSC scores were significantly related to work
limitations, while neuropsychological test results were
not. Furthermore, de Vet et al., [24] stated that in situa-
tions in which a gold standard is lacking, construct
Table 3 Measurement characteristics Cognitive Symptom Checklist-Work Dutch version (n=341)
Valid n (missing or ‘not applicable’) Meana (SD) Range (0–100) n (%) at floor n (%) at ceiling Cronbach’s α
Working memory (8 items) 341 (0) 32.2 (19.0) 0–85.7 27 (8) 0 (0) 0.93
Executive function (11 items) 336 (5) 19.8 (15.8) 0–72.7 52 (15) 0 (0) 0.94
Total score (19 items) 341 (0) 25.1 (15.8) 0–76.5 20 (6) 0 (0) 0.95
a Each scale is scored from 0 to 100, with higher score indicating higher cognitive symptoms. Alphas calculated in SPSS (listwise deletion)
Table 4 Comparing means (n=341)
Variable CSC-W DV, M (SD) P value
Work functioning (WRFQ2.0) (n=318)
High (n=93, 29 %) 14.1 (10.8) <0.001a
Medium (n=111, 35 %) 24.2 (13.1)
Low (n=114, 36 %) 35.4 (15.0)
Fatigue (CIS) (n=340)
Low (n=114, 34 %) 20.8 (13.9) 0.001b
Medium (n=113, 33 %) 26.3 (15.8)
High (n=113, 33 %) 28.5 (16.6)
Depressive symptoms (PHQ-9) (n=341)
Low (n=301, 88 %) 23.2 (14.7) <0.001
High (n=40, 12 %) 39.6 (16.2)
Perceived health (SF-36) (n=335)
High (n=256, 76 %) 24.5 (14.8) 0.14
Low (n=79, 24 %) 27.5 (18.4)
CSC-W DV, Cognitive Symptom Checklist-Work, Dutch version,WRFQ
2.0, Work Role Functioning Questionnaire, CIS Checklist Individual
Strengths, PHQ-9 Patient Health Questionnaire-9, SF-1 Short-Form 36
a Post Hoc analyses (Bonferroni) showed significant differences between
all groups
b Post Hoc analyses (Bonferroni) showed no significant difference be-
tween the middle and high fatigue group
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validation should be used to provide evidence of validity.
Although self-report measures are known to have a low
correlation with a neuro-psychological assessment of
cognitive function in everyday life [3, 10, 35], it would
be interesting to investigate the relationship between the
CSC-W DV and neuro-psychological assessments ap-
proaches specifically developed to assess various types
of cognitive functioning in problematic work tasks.
Conclusion
This study indicates that the CSC-W DV can be used to
measure cognitive symptoms in working patients with dif-
ferent cancer diagnoses. Knowledge about work-specific
cognitive symptoms may improve guidance such as work
accommodations to support cancer patients at work. To
improve the quality of life and functioning at work, it is
important to know which cognitive problems cancer pa-
tients experience. To make the CSC-W DV suitable for
use on an individual level, it is recommended to develop
cut-off points. Future comparative studies are now possi-
ble in three different countries with three different social
systems and policies towards cancer and work. More in-
formation on the responsiveness of the CSC-W DV is
needed when the CSC-W DV is used for monitoring cog-
nitive function of working cancer patients and further lon-
gitudinal studies are needed to investigate the relationship
between cancer diagnosis and cognitive functioning at
work.
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